In this contribution we present the main features of the plasma coagulation controller (PCC) device, a cold atmospheric pressure plasma source based on the dielectric barrier terms of discharge repetition rate (1-20 kHz) and applied voltage (2-8 kV). Helium is used as is suitable for application on the human body. Emission spectroscopy analysis is performed: the presence in the plasma of reactive oxygen species (ROS) and reactive nitrogen species (RNS) is and in vitro blood coagulation. Interestingly, tests on blood samples exposed to the helium plasma KEY WORDS: plasma medicine, atmospheric pressure plasma applications, dielectric barrier discharge, biomedical applications
I. INTRODUCTION
applications. It deals with the use of cold plasmas produced at atmospheric pressure at present include disinfection, 1 wound healing, 2 blood coagulation, [3] [4] [5] and cancer cell treatment. 6, 7 The driving idea behind plasma medicine is to perform a very localized and nonthermal (few watts of power) treatment of the human/animal body substrate. 1 and the dielectric barrier discharge (DBD) concepts (described in section 2). In both cases, a neutral gas is ionized by applying a time-varielectron populations and "cold" ions (and neutral particles) close to room temperature. At atmospheric pressure the main gas (typically helium or argon) mixes with surround-ing air, so the produced plasma is enriched with ROS and RNS as a result of the chemical reactions induced by the energetic electrons. Though the mechanisms behind the plasma-living matter interaction are not fully understood, the aforementioned excited charged particles (ion and electrons) are considered as the main agents of the observed In this contribution, we present a novel plasma medicine tool, based on a DBD
II. PLASMA COAGULATION CONTROLLER
A non-thermal plasma source at atmospheric pressure has been realized upon exploiting -age between two electrodes separated by a dielectric material ( Fig. 1 ) with the goal of limiting the current associated to the breakdown. On the plasma coagulation controller (PCC) device, high voltage (V app range is 2-8 kV) is achieved through a ferrite core coil mounted on the source head and directly connected to the central electrode covered by a Pyrex tube (dielectric). A metallic ring housed on an external concentric Pyrex tube acts as a grounded electrode. The device is controlled by an Arduino Leonardo microor argon can be used as a working gas for the PCC. However, in this contribution we will present only helium plasma treatment. The device has been characterized using a fast multichannel oscilloscope, a passive high voltage probe and an AC current probe. In Fig. 2 , the time trace of the applied voltage on the central electrode is shown. Current I plate has been also measured on a metallic grounded plate placed at a distance of 1 cm from the source head. The current waveform can be estimated on the order of:
(1) 
III. SPECTROSCOPIC ANALYSIS
Plasma emission was analyzed using a PI IsoPlane spectrometer of 320 mm focal length, 2048 one is 1.5 nm, and the second one is 0.087 nm (at 300 nm) when using an entrance slit of focal length of 10 mm and a diameter of 8 mm diameter, focusing the plasma image on a end was coupled to the spectrometer entrance slit. The spectral response of the entire diagnostic had been measured from 350 nm to 750 nm, using an integrating sphere. The optical head was placed perpendicular to the plasma plume just outside the plasma source head.
resolution grating (Fig. 3) . Integrating time is on the order of few seconds. Clearly visible are the N 2 ro-vibrational lines of the second positive system (SPS) and the N 2 + lines of the helium I and the oxygen I triplet at 777 nm. H and H lines are also above the noise level. The rotational temperatures of the OH and N 2 molecules were deduced from their rotational spectra. 8 The two bands of OH at around 309 nm and and the N 2 band at diagnostic instrumental function and the dispersion. The temperature corresponding to the best match between the experimental spectrum and the simulations was found by
The rotational temperatures of the two molecules were fully compatible, and ranged between 317 ± 22 K and 279 ± 27 K.
IV. BIOLOGICAL TESTS

gram-negative and gram-positive bacterial strains, usually involved in wound infections:
Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa. Bacteria were grown in the proper medium at 37°C. On the day of the experiment, 500 L of the culture were transferred to 5 mL of fresh medium and incubated under continuous shaking until the absorbance at 590 nm was 0.1. Bacteria were then serially diluted to obtain suspension concentrations of 106 colony-forming units (CFU) per mL. Afterwards, 200 L of the solutions containing various amounts of microbes were placed in 24-well tissue culture plates (NUNC, Roskilde, Denmark; growth area 2 cm 2 , and well volume 3.5 mL). Then bacterial cultures were exposed to helium plasma produced with PCC for different time periods. Bacterial vitality was evaluated by counting colonies. As shown in Fig. 5 , relative vitality of bacteria dropped to less than 50% after only 15 s of plasma exposure at the standard condition and kept decreasing over time until reaching almost 100% after 2 min (see Fig. 5 ).
--1,9 ) was used and reported in the same plot.
colonies.
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FIG. 6:
sults with RF plasma treatment are also showncellular production of ROS and nitric oxide (NO) molecules as a response to the PCC -ence of ROS (left) and NO (right) for the control (cells exposed to air), with treatment at intracellular ROS increased according to the treatment duration, suggesting a possible link with PCC action. On the other side, NO behavior displayed a sudden increase after only 15 s of treatment, but slightly decreased for longer treatments. The detailed cellular mechanisms involving in ROS and NO production will be further investigated in the future.
V. ACCELERATED BLOOD COAGULATION: IN VITRO STUDIES
Finally, the ability of PCC to accelerate blood coagulation in vitro has been tested repeatedly.
Blood samples were withdrawn from patients following anticoagulant therapy. In this setting, recent clinical studies have underlined the importance of maintaining an optimal anticoagulation state also during surgery to warrant patient protection. In fact, the incidence of thromboembolic events is higher around the time of the procedure. 10 Nonetheless, maintenance of periprocedural anticoagulation raises the bleeding risk. In this setting, the availability of a device that could facilitate hemostasis and prevent infections around the peri-procedural phase would be very helpful. Blood samples were withdrawn and stored in Vacutainer tubes containing ethylenediaminetetraacetic acid (EDTA) and kept at 4 -2 was added to contrast 15 s, 30 s, or 1 min, respectively. Control (CTRL) samples were exposed to air at room temperature (no treatment). After the treatment, the blood was gently removed, and the
FIG. 7:
plot refer to control cells exposed to air (nt) presence of blood clots on the well surface evaluated immediately (data not shown) and at 24 h after the treatment. Figure 8 shows a representative image of a plate 24 h posttreatment. Each blood clot was photographed and the image measured using a cus-(GraphPad Software). As shown in Fig. 9 , all the treatments showed a large increase in blood coagulation (expressed as area of coagulated blood remaining in each well) (N = one-way analysis of variance (ANOVA) (15 s: p < 0.0099; 30 s: p < 0.0007; 1 min: p < of the replicates ± standard error mean.
VI. CONCLUSION
FIG. 8:
this work, has been built, characterized with spectroscopic analysis, and successfully that are likely to be involved in the interaction with living matter has been highlighted. 
